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Major histocompatibility complex class II plays a key
role in the immune response, by presenting processed
antigens to CD4+ lymphocytes. Major histocompatibility
complex class II expression is controlled at the tran-
scriptional level by at least four trans-acting genes:
CIITA, RFXANK, RFX5 and RFXAP. Defects in these
regulatory genes cause MHC class II immunodeficiency,
which is frequent in North Africa. The aim of this study
was to describe the immunological and molecular char-
acteristics of ten unrelated Moroccan patients with
MHC class II deficiency. Immunological examinations
revealed a lack of expression of MHC class II molecules
at the surface of peripheral blood mononuclear cells,
low CD4+ T lymphocyte counts and variable serum
immunoglobulin (IgG, IgM and IgA) levels. In addition,
no MHC class II (HLA DR) expression was observed on
lymphoblasts.
The molecular analysis identified the same homozy-
gous 752delG26 mutation in the RFXANK genes of all
patients. This finding confirms the association between
the high frequency of the combined immunodeficiency
and the defect in MHC class II expression and provides
strong evidence for a founder effect of the 752delG26
mutation in the North African population. These find-
ings should facilitate the establishment of molecular
diagnosis and improve genetic counseling for affected
Moroccan families.
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